Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
22 May 2012Website:
http://www.clearpointneuro.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 20:38:00 GMTDividend
Analysts recommendations
Institutional Ownership
CLPT Latest News
ClearPoint (CLPT) announces the full market release of the SmartFrame OR platform, intended for performing DBS, and Prism Neuro Laser Therapy System for providing thermal therapy.
The consensus price target hints at an 81.5% upside potential for ClearPoint Neuro (CLPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Analysts' average price target for ClearPoint Neuro (CLPT) suggests a potential 70.7% increase in the stock. Though this metric is not always reliable, the consensus among analysts in raising earnings estimates does indicate positive potential for the stock.
ClearPoint Neuro: Multiple Compression due to Macroeconomic Factors
ClearPoint Neuro (CLPT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ClearPoint Neuro, Inc. (CLPT) Q4 2023 Earnings Call Transcript
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.18 per share a year ago.
ClearPoint's (CLPT) Prism Neuro Laser Therapy System is likely to provide an integrated solution for precise and more efficient laser interstitial thermal therapy.
SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its 2023 fourth quarter and full year on Tuesday, March 12th, after the market close.
ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to provide fast, peri-procedural segmentation of the cortical structures of the brain.
- 1(current)
What type of business is ClearPoint Neuro?
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
What sector is ClearPoint Neuro in?
ClearPoint Neuro is in the Healthcare sector
What industry is ClearPoint Neuro in?
ClearPoint Neuro is in the Medical Devices industry
What country is ClearPoint Neuro from?
ClearPoint Neuro is headquartered in United States
When did ClearPoint Neuro go public?
ClearPoint Neuro initial public offering (IPO) was on 22 May 2012
What is ClearPoint Neuro website?
https://www.clearpointneuro.com
Is ClearPoint Neuro in the S&P 500?
No, ClearPoint Neuro is not included in the S&P 500 index
Is ClearPoint Neuro in the NASDAQ 100?
No, ClearPoint Neuro is not included in the NASDAQ 100 index
Is ClearPoint Neuro in the Dow Jones?
No, ClearPoint Neuro is not included in the Dow Jones index
When does ClearPoint Neuro report earnings?
The next expected earnings date for ClearPoint Neuro is 08 August 2024